KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Sales (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Sales for 15 consecutive years, with 0.02% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 11.0% to 0.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.05%, a 17.0% decrease, with the full-year FY2025 number at 0.05%, down 17.0% from a year prior.
  • Return on Sales was 0.02% for Q4 2025 at Supernus Pharmaceuticals, up from 0.24% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.22% in Q3 2024 to a low of 0.24% in Q3 2025.
  • A 5-year average of 0.05% and a median of 0.04% in 2021 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: surged 32bps in 2024, then crashed -45bps in 2025.
  • Supernus Pharmaceuticals' Return on Sales stood at 0.02% in 2021, then skyrocketed by 892bps to 0.15% in 2022, then tumbled by -95bps to 0.01% in 2023, then surged by 1176bps to 0.09% in 2024, then plummeted by -122bps to 0.02% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Return on Sales are 0.02% (Q4 2025), 0.24% (Q3 2025), and 0.14% (Q2 2025).